Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 8Hematologic Neoplasms 3Thyroid Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Glioma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Astrocytoma 1

Interventions

veliparib 1dabrafenib 1Taxes 1Plasmapheresis 1Pharmacogenomic Testing 1Paclitaxel 1Oxaliplatin 1Kidney Transplantation 1Drug Therapy 1Dexamethasone 1Carboplatin 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Renal Insufficiency × dabrafenib × Clear all
NCT01907802 2018-08-14

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Terminated
8 enrolled

Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡